Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Katarzyna Łosińska, Are Hugo Pripp, Gunnstein Bakland, Bjørg-Tilde Svanes Fevang, Lene Kristin Brekke, Ada Wierød, Mariusz Korkosz, Glenn Haugeberg
OBJECTIVE: We aim to compare drug effectiveness and persistence between reference etanercept (ETN) and ETN biosimilar SB4 in psoriatic arthritis (PsA) patients naïve to ETN and to investigate drug effectiveness and persistence in those undergoing mandatory non-medical switch from ETN to SB4. METHODS: Retrospective comparative database study including 1138 PsA patients treated with ETN or SB4 (years 1999-2021) in Norway. Disease activity score in 28 joints (DAS28) and drug persistence were compared between unmatched ETN (n=644) and SB4 (n=252) cohorts and in matched analyses (n=144, both cohorts) at baseline using propensity score (PS) to adjust for confounders...
April 10, 2024: Arthritis Care & Research
#22
JOURNAL ARTICLE
Alen Zabotti, Filippo Fagni, Laure Gossec, Ivan Giovannini, Michael Sticherling, Annarita Tullio, Xenofon Baraliakos, Gabriele De Marco, Salvatore De Vita, Enzo Errichetti, Luca Quartuccio, Ettore Silvagni, Josef S Smolen, Ilaria Tinazzi, Abdulla Watad, Georg Schett, Dennis G McGonagle, David Simon
OBJECTIVE: Subjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk of PsA but scant real-world data exist. Our aims were to (1) estimate the probability of PsA development in subclinical PsA, (2) characterise subclinical PsA symptoms and (3) determine the clinical patterns at PsA diagnosis. METHODS: Patients with PsO, mainly subclinical PsA, were evaluated longitudinally in two European cohorts...
April 10, 2024: RMD Open
#23
JOURNAL ARTICLE
Piero Ruscitti, Ilenia Pantano, Giulia Cataldi, Martina Gentile, Francesco Arrigoni, Luca Riccio, Sabrina Marrone, Daniele Mauro, Francesco Ursini, Maria Esposito, Antonio Barile, Maria Concetta Fargnoli, Roberto Giacomelli, Francesco Ciccia, Paola Cipriani
OBJECTIVE: To evaluate the short-term effectiveness of guselkumab in patients with psoriatic arthritis (PsA) and suggestive features of axial involvement in a prospective "real-life" multicentre cohort. METHODS: Between June 2022 and June 2023, PsA patients with axial involvement were evaluated if treated at least for 4 months with guselkumab. The effectiveness was evaluated by BASDAI, ASDAS, DAPSA, and achievement of BASDAI ≤ 4, also exploiting predictive factors...
April 10, 2024: Rheumatology
#24
JOURNAL ARTICLE
Blanca Hernández-Cruz, Lucía Otero-Varela, Mercedes Freire-González, Noemí Busquets-Pérez, Alfredo Javier García González, Manuel Moreno-Ramos, Juan Maria Blanco-Madrigal, Sara Manrique-Arija, Eva Perez-Pampin, Dolores Ruiz-Montesino, Fernando Sánchez-Alonso, Carlos Sanchez-Piedra, Isabel Castrejón
OBJECTIVES: To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). METHODS: We analysed data from patients included in BIOBADASER 3.0 and treated with JAKi or TNFi from 2015 to 2023 and estimated the incidence rate ratio (IRR) of adverse events and persistence. RESULTS: A total of 6826 patients were included...
April 9, 2024: Annals of the Rheumatic Diseases
#25
JOURNAL ARTICLE
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
INTRODUCTION: The concept of severity in a multidomain disease such as psoriatic arthritis (PsA) is still not well defined. The aim of this study was to identify the clinical characteristics of patients with severe peripheral PsA. METHODS: Retrospective analysis of a longitudinal cohort. Demographic and clinical characteristics of patients with PsA were collected at baseline and at last follow-up. We defined the severe population using the modified Composite Psoriatic Disease Activity Index (mCPDAI); which excludes ankylosing spondylitis quality of life scale)...
April 9, 2024: Rheumatology and Therapy
#26
REVIEW
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna
Psoriasis is now considered a systemic disease, and several comorbidities have been described such as cardiovascular diseases, neurologic and psychiatric disorders, chronic inflammatory bowel disease, psoriatic arthritis, etc. Regarding cardiovascular comorbidities, major adverse cardiovascular events have been reported in psoriasis patients by multiple epidemiologic studies. Moreover, smoking, obesity, metabolic syndrome, hypertension, dyslipidemia, diabetes and reduced physical activity are associated with psoriasis, increasing cardiovascular risk...
April 9, 2024: Dermatology and Therapy
#27
JOURNAL ARTICLE
Xudong Sang, Tian Gan, Gai Ge, Dan Li, Youming Mei, Chun Pan, Siyu Long, Bibo Xie, Xiaobing Yu, Zhiming Chen, Hongsheng Wang
BACKGROUND: Psoriasis, a systemic disorder mediated by the immune system, can appear on the skin, joints, or both. Individuals with cutaneous psoriasis (PsC) have an elevated risk of developing psoriatic arthritis (PsA) during their lifetime. Despite this known association, the cellular and molecular mechanisms underlying this progression remain unclear. METHODS: We performed high-dimensional, in-depth immunophenotyping of peripheral blood mononuclear cells (PBMCs) in patients with PsA and psoriasis vulgaris (PsV) by mass cytometry...
2024: Journal of Immunology Research
#28
REVIEW
Renad F Alharthy, Joud M Alharthy, Razan O Bawazir, Renad I Katib, Fayez S Alharthy
Psoriasis is a chronic autoimmune inflammatory skin disease that is associated with other conditions, one of them being psoriatic arthritis (PsA). Apremilast, a phosphodiesterase-4 inhibitor, displayed promising results in multiple trials for patients with PsA. This systematic review and meta-analysis aims to showcase its efficacy and safety when compared to placebo. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) was adopted after registration on the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023476245)...
March 2024: Curēus
#29
JOURNAL ARTICLE
Yeon Mi Hwang, Qi Wei, Samantha N Piekos, Bhargav Vemuri, Sevda Molani, Philip Mease, Leroy Hood, Jennifer Hadlock
BACKGROUND: Immune-mediated inflammatory diseases (IMIDs) are likely to complicate maternal health. However, literature on patients with IMIDs undergoing pregnancy is scarce and often overlooks the presence of comorbidities. We aimed to evaluate the impact of IMIDs on adverse pregnancy outcomes after assessing and addressing any discrepancies in the distribution of covariates associated with adverse pregnancy outcomes between patients with and without IMIDs. METHODS: We conducted a retrospective cohort study using data from an integrated U...
February 2024: EClinicalMedicine
#30
Jason Dossantos, Jella An
PURPOSE: This study seeks to highlight and explore the occurrence of uveitis with obstructive peripheral anterior synechiae (PAS) after a combined OMNI canaloplasty and Hydrus microstent implantation with phacoemulsification, particularly in a patient with a background of psoriatic arthritis. OBSERVATIONS: A 56-year-old male with a medical history of psoriatic arthritis (in remission for 10 years) and primary open-angle glaucoma (POAG) underwent a combined OMNI canaloplasty and Hydrus microstent with phacoemulsification...
2024: Journal of Current Glaucoma Practice
#31
JOURNAL ARTICLE
Dario Graceffa, Arianna Zangrilli, Giacomo Caldarola, Viviana Lora, Diego Orsini, Gala Moretta, Gianluca Pagnanelli, Alessia Provini, Cinzia Masini, Mauro Bavetta, Domenico Giordano, Antonio Richetta, Ersilla Tolino, Luca Bianchi, Ketty Peris, Francesca Sperati, Claudio Bonifati
BACKGROUND: IL-23 inhibitors were recently approved for the treatment of skin psoriasis and psoriatic arthritis (PsA). Risankizumab, a humanized monoclonal antibody that specifically binds the p19 subunit of IL-23, has proven effective on PsA in two randomized controlled trials. To date, only a few real-world data are available on this topic. METHODS: Our study aimed to prospectively evaluate the effectiveness of risankizumab in patients with PsA in a real-world setting...
April 7, 2024: International Journal of Dermatology
#32
JOURNAL ARTICLE
Arwa S Amer, Ahmed Y Al Shambaky, Seham G Ameen, Amira Khalil Sobih
BACKGROUND: Enthesopathy is considered a crucial aspect of assessment and outcome in psoriatic arthritis (PsA). Musculoskeletal ultrasound (MSUS) is a critical tool for accurately detecting enthesitis. Recent research focuses on identifying simple biomarkers for detecting and monitoring psoriatic enthesopathy. Red cell distribution width (RDW), mean platelet volume (MPV), and neutrophil/lymphocyte ratio (NLR) are components of a complete blood count (CBC) and are reliable bio-inflammatory markers in various rheumatic diseases...
April 8, 2024: Clinical Rheumatology
#33
JOURNAL ARTICLE
Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, Lennart Jacobsson, Michael J Nissen, Eirik Klami Kristianslund, Maria José Santos, Dan Nordström, Ziga Rotar, Bjorn Gudbjornsson, Fatos Onen, Catalin Codreanu, Ulf Lindström, Burkhard Möller, Tore K Kvien, Anabela Barcelos, Kari K Eklund, Matija Tom, Thorvardur Jon Love, Gercek Can, Ruxandra Ionescu, Anne Gitte Loft, Herman Mann, Karel Pavelka, Marleen Van De Sande, I E Van Der Horst-Bruinsma, Manuel Pombo Suarez, Carlos Sánchez Piedra, Gary J Macfarlane, Florenzo Iannone, Brigitte Michelsen, Lise Hejl Hyldstrup, Niels Steen Krogh, Mikkel Østergaard, Merete Lund Hetland
OBJECTIVE: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment. METHODS: Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted cox regression analyses and Chi-squared test, respectively)...
April 4, 2024: Joint, Bone, Spine: Revue du Rhumatisme
#34
JOURNAL ARTICLE
Rossella Talotta, Maria Rita Aiello, Roberto Restuccia, Ludovico Magaudda
BACKGROUND AND OBJECTIVE: In this review, we discuss evidence concerning the management of psoriatic arthritis (PsA) patients with non-pharmacological interventions and additionally develop physical training protocols that could be prescribed to these patients. METHODS: We selected 110 articles, published on PubMed and Google Scholar databases from 1972 to date, investigating the effects of generic hygienic-dietary recommendations and training programs in PsA or psoriasis (PSO) individuals...
April 5, 2024: Alternative Therapies in Health and Medicine
#35
JOURNAL ARTICLE
Or Hen, Andrea Di Matteo, Sayam R Dubash, Gabriele De Marco, Ai Lyn Tan, Paul Emery, Richard J Wakefield, Dennis G McGonagle, Philip Helliwell, Helena Marzo-Ortega
AIMS: To investigate the prevalence and distribution of bone erosions in an early psoriatic arthritis (PsA) population using conventional radiography (CR) and to explore the agreement between CR and ultrasound (US) detected bone erosions. METHODS: Newly diagnosed, treatment naïve PsA patients fulfilling the ClASsification for Psoriatic Arthritis (CASPAR) classification criteria of ≤5 years symptom duration were recruited as part of the Leeds Spondyloarthropathy Register for Research and Observation and underwent CR and US examination of hands and feet...
April 5, 2024: RMD Open
#36
JOURNAL ARTICLE
Marco Matucci-Cerinic, Francesco Ciccia, Rosario Foti, Alessandro Giunta, Francesco Loconsole, Francesca Prignano, Rossana Scrivo, Giampiero Girolomoni
BACKGROUND AND OBJECTIVES: Psoriasis (PsO) and psoriatic arthritis (PsA) are often undertreated and require a multidisciplinary approach. In recent years, patent expiration has allowed the introduction of tumor necrosis factor inhibitor (anti-TNF) biosimilars, which have stimulated a significant increase in the use of biological therapies. This article reports the findings of a multidisciplinary approach to achieve a consensus on the use of adalimumab in patients with PsO or PsA. METHODS: A voting panel of 36 Italian dermatologists and rheumatologists were chosen by eight Italian clinicians (the Board), to provide a consensus on the real-world management of PsO and PsA with adalimumab using the Delphi Method, comprising three survey rounds...
March 2024: Rheumatol Immunol Res
#37
JOURNAL ARTICLE
Maximilian Casey, Sonia Pannu, Saffia Bajwa, Alí Duarte-García, Michael Putman
BACKGROUND: Neuroinflammatory adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to date have compared the real-world risk of TNFs to other new users of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARD). The objective of this study is to describe the risk of neuroinflammatory disease after initiation b/tsDMARDs. METHODS: This new-user comparative effectiveness cohort study utilized a large US-based electronic health-records database to describe the unadjusted incidence of neuroinflammatory adverse events over a 3-year period...
April 3, 2024: Arthritis Care & Research
#38
JOURNAL ARTICLE
Luise Holberg Lindgren, Annette de Thurah, Tanja Thomsen, Merete Lund Hetland, Mette Aadahl, Sofie Bech Vestergaard, Sara Danshøj Kristensen, Bente Appel Esbensen
When newly diagnosed with inflammatory arthritis (IA), acquiring self-management skills is beneficial, to enhance quality of life. The personal beliefs and mental representations patients hold about their illness, known as illness perception, significantly influence the development of these skills. Recognizing characteristics that affect illness perception is key to identifying patients requiring additional support for the development of self-management skills. This study aimed at identifying the sociodemographic and clinical characteristics associated with a negative illness perception...
April 2, 2024: Rheumatology International
#39
JOURNAL ARTICLE
Daniel G Fernández-Ávila, Wilson Bautista-Molano, María Lorena Brance, María Gabriela Ávila Pedretti, Rubén Burgos Vargas, José Francisco Díaz Coto, Luis Arturo Gutiérrez, Marwin Gutiérrez, Enrique Giraldo Ho, Sebastián Eduardo Ibáñez Vodnizza, Edwin Jáuregui, Vanessa Ocampo, Penélope Esther Palominos, Daniel Ruben Palleiro Rivero, Guillermo Andrés Quiceno, Fernando Andrés Sommerfleck, Luis Enrique Vega Espinoza, Oscar Vega Hinojosa, Claudia Vera Barrezueta, Inés Corbacho, Vanesa Laura Cosentino, Annelise Goecke Sariego, Gustavo Gomes Resende, Lina María Saldarriaga-Rivera, Cesar Francisco Pacheco Tena, Gustavo Citera, Carlos Lozada, Roberto Ranza, Percival D Sampaio-Barros, Emilce Schneeberger, Enrique R Soriano
OBJECTIVE: Psoriatic arthritis (PsA) is chronic disease that compromise multiple domains, and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective is to generate evidence-based recommendations on the management of PsA in PANLAR countries. METHODS: We used the Grading of Recommendations, Assessment, Development and Evaluation GRADEADOLOPMENT approach to adapt the 2019 recommendations of the European League Against Rheumatism (EULAR)...
April 1, 2024: Journal of Rheumatology
#40
JOURNAL ARTICLE
Ignacio Braña, Marta Loredo, Estefanía Pardo, Stefanie Burger, Eva Fernández-Bretón, Rubén Queiro
OBJECTIVE: Information on the persistence of tofacitinib in PsA is scarce in real-life conditions. Our objective was to analyze persistence and safety of tofacitinib under these conditions. METHODS: Single-center retrospective longitudinal observational study of all PsA patients that received at least one dose of tofacitinib. Main focus was on adverse events and drug survival. Drug survival was analyzed by Kaplan-Meier curves and persistence explanatory factors by multivariate Cox regression models...
April 1, 2024: Journal of Rheumatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
